Rivaroxaban is a novel oral anticoagulant (NOAC) drug. It has several FDA-approved and off-label clinical uses.

**FDA Approved Indications**

- In 2011 the FDA approved rivaroxaban for patients undergoing elective orthopedic surgery like knee and hip replacement surgery postoperative thromboprophylaxis of DVT.

- In 2011 the FDA approved its use in primary and secondary stroke prevention in people with cardiac arrhythmia, most commonly in nonvalvular Atrial fibrillation.

- In 2012, the FDA approved rivaroxaban for treatment after an acute venous thromboembolism event and recurrence of blood clots.

- In 2017 the FDA approved the use of rivaroxaban to reduce the continued risk of venous thromboembolism

- In 2018, the FDA approved it for secondary prevention after acute coronary syndrome (ACS) or peripheral arterial disease (PAD) as an add-on to clopidogrel and aspirin therapy after stabilization with initial management

- In 2019, the FDA approved rivaroxaban for hospitalized adult patients with an acute medical illness at risk for thromboembolic complications due to restricted mobility and other risk factors.

**Other Off-label Uses**

- treatment of acute heparin-induced thrombocytopenia as initial therapy in hemodynamically stable patients or following initial therapy with a parenteral non-heparin anticoagulant.

- Post-percutaneous coronary intervention with stent placement (after stabilization with initial management) in patients with nonvalvular atrial fibrillation

- Acute, symptomatic superficial vein thrombosis